Gyroscope Therapeutics, a company focused on retinal diseases, has appointed Soraya Bekkali CEO, chief medical officer and director of its board. Before Gyroscope, Bekkali was senior vice president and chief medical officer of Lysogene SAS and previously, she was global head of the ophthalmology business unit at Sanofi, where she spent 10 years in various positions.
Keith A. Katkin has been elected Urovant Sciences' CEO and most recently, he was president and CEO of Avanir Pharmaceuticals Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?